Table 1.
Variable | Women (n=1013) | Men (n=1065) |
---|---|---|
General characteristics | ||
Age (years) | 45 [40–50] | 46 [41–51] |
Height (cm) | 163±6 | 176±7 |
Weight (kg) | 65.4±11.6 | 81.1±12.2 |
BMI (kg/m2) | 24.5±4.2 | 26.2±3.6 |
Smoking (active/ex/never; %) | 19/21/60 | 22/36/42 |
TSH and thyroid hormones | ||
TSH (mU/L) | 1.54 [1.08–2.08] | 1.47 [1.03–2.04] |
FT4 (ng/dL) | 1.25 [1.15–1.35] | 1.34 [1.23–1.44] |
FT3 (pg/mL) | 3.0 [2.8–3.2] | 3.4 [3.1–3.6] |
TT3 (ng/dL) | 120 [105–140] | 118 [107–129] |
Blood pressure and heart rate | ||
Systolic BP (mm Hg) | 121±13 | 130±12 |
Diastolic BP (mm Hg) | 77±9 | 82±9 |
Heart rate (average; bpm) | 68±9 | 64±10 |
Echocardiographic parameters | ||
Systolic function | ||
Ejection fraction (%) | 67±8 | 65±8 |
s′ (mm/s) | 80±11 | 79±12 |
LVESD (mm) | 28±4 | 32±4 |
Diastolic function | ||
E (cm/s) | 79±14 | 71±13 |
A (cm/s) | 62±11 | 59±10 |
e′ (mm/s) | 96±21 | 87±18 |
a′ (mm/s) | 86±15 | 92±15 |
LV structure | ||
LV mass (g) | 121±29 | 177±39 |
LVMI (g/m2) | 71±14 | 90±18 |
LVEDD (mm) | 45±4 | 49±4 |
Relative wall thickness | 0.36±0.06 | 0.39±0.07 |
Subjects on thyroid or antihypertensive medication, with antithyroperoxidase antibodies above clinical cut-off, and with TSH levels outside the reference range were excluded from further analyses. Data are mean±SD or medians [first, third quartile] in case of non-Gaussian distribution. Conversion factor for FT3 from pg/mL to pmol/L and for TT3 from ng/dL to nmol/L is ×0.0154; conversion factor for FT4 from ng/dL to pmol/L is ×12.87.
T3, triiodothyronine; TSH, thyrotropin; FT4, free thyroxine; FT3, free T3; TT3, total T3; LVESD, left ventricular end-systolic diameter; s′, systolic mitral annulus velocity; E, early diastolic transmitral flow velocity; A, late diastolic transmitral flow velocity; e′, pulsed-wave tissue Doppler early diastolic component; a′, pulsed-wave tissue Doppler late diastolic component; LVMI, left ventricular mass index; LVEDD, left ventricular end-diastolic diameter.